New Delhi, May 20th, 2026: Eris Lifesciences Limited (“ErisLifesciences” or the “Company”) (BSE: 540596; NSE: ERIS), a leading Indian branded formulations manufacturing company, today announced its earnings for the quarter and full year ended March 31, 2026.
Q4 and FY2026 Financial Performance Summary (Consolidated):
| Particulars (INR Cr) | Q4 FY26 | Q4 FY25 | YoY (%) | FY2026 | FY2025 | YoY (%) |
| Revenue from Operations | 757 | 705 | 7% | 3,129 | 2,894 | 8% |
| Gross Profit | 571 | 535 | 7% | 2,334 | 2,180 | 7% |
| EBITDA | 274 | 252 | 8% | 1,120 | 1,017 | 10% |
| EBITDA Margin (%) | 36.2% | 35.8% | 35.8% | 35.2% | ||
| Profit After Tax (PAT) | 279 | 102 | 173% | 648 | 375 | 73% |
| PAT Margin (%) | 36.9% | 14.5% | - | 20.7% | 12.9% |
Q4 and FY2026 Key Financial Highlights:
- DBF business revenue growth of 12% YoY in Q4 and 11% YoY in FY26 – EBIDTA margin 37%
- Consolidated Revenue growth 7% YoY in Q4 and 8% YoY in FY26 – EBIDTA margin 36%
- Consolidated Q4 PAT Rs. 279 Cr with a 174% growth, FY26 PAT Rs. 648 Cr, with a 73% growth
- Net debt as of March 31, 2026, stood at Rs. 2,255 Cr
Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said, “Our Domestic Formulations business delivered a 11% revenue growth in FY26 with a 12% EBIDTA growth and industry leading EBIDTA margin of 37%. Our Insulins franchise has outpaced market growth by 5x in FY26 with a market share expansion from 12% to 16%. Our GLP brand Sundae has gotten off to a strong start, which reflects the present standing of the company in the Injectable Diabesity space. Sundae ranks #1 by volume (among injectables)in its very first month of launch, which validates our thesis of being able to leverage our Insulins platform to secure a strong position in the GLP segment.”
